CDT Equity Posts $(4.06)M Q1 Loss, EPS $(5.56) — Strategic Shift to AI-Driven Pharma Platform
CDT is trading near its 52-week low of $0.34 (3.0% above the low).
Summary
CDT Equity reported a Q1 2026 net loss of $(4.06)M, a modest improvement from $(4.75)M a year ago, with diluted EPS of $(5.56) versus $(3,670.27) in Q1 2025 — the dramatic EPS swing reflects the March 2026 reverse split. The 10-Q confirms the company's pivot from traditional biotech to a data-driven platform leveraging AI through its Sarborg partnership to repurpose deprioritized assets. The lean, licensing-focused model aims for capital efficiency, but the company remains pre-revenue with a market cap near $1.7M and shares trading at $0.35, near the 52-week low. This follows the June disclosure of a $127.5M stake in Sarborg, which provides a potential value anchor but is illiquid. The Nasdaq deficiency notice for late filing of this very 10-Q adds a compliance overhang.
At the time of this announcement, CDT was trading at $0.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7M. The 52-week trading range was $0.34 to $468.00. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.